Solifenacin Succinate

[OVESI] VESIcare® 5mg/Tab ATC Code : G04BD08

中文名: 衛喜康膜衣錠 《安斯泰來》

適應症: 對於膀胱過動症病人所伴隨之急迫性性尿失禁、頻尿、尿急等之症狀性治療。

藥理分類: Anticholinergic Agent; Genitourinary Smooth Muscle Relaxants.

作用機轉: Inhibits muscarinic receptors resulting in decreased urinary bladder contraction,

increased residual urine volume, and decreased detrusor muscle pressure.

用法用量: **Aadministraiton**: orally, taken with or without food.

Dosage regimens:

5 mg QD, and if well tolerated may be increased to 10 mg QD.

Do not exceed 5 mg QD in patients with:

♦ severe renal impairment (CLcr < 30 mL/min).
</p>

- ♦ concomitant use of potent CYP3A4 inhibitors.

Use of VESIcare is **not recommended** in patients with severe hepatic impairment (Child-Pugh C).

不良反應: 可能引起口乾、便秘、消化不良、乾眼症、視力模糊、尿滯留等。

交互作用:

- Erythromycin, ketoconazole, fluconazole, itraconazole, voriconazole: ↑ plasma concentration of solifenacin and ↑ risk of QT-interval prolongation.
- Potassium: may result in risk of gastrointestinal lesions.
- Scopolamine: ↑ risk of CNS adverse reactions, intestinal obstruction, and urinary retention.

注意事項: 1.空腹或與食物一起服用皆可。以水整粒吞服。

1.應避免與強力的 CYP3A4 抑制劑(如 erythromycin、clarithromycin)或抗黴菌製劑(ketoconazole、itraconazole 及 miconazole)並用。

2.青光眼、尿液滯留性前列腺腫大之病患及孕婦禁用。

懷 孕 期: 1.Adverse events were observed in some animal reproduction studies.

2. Because animal reproduction studies are not always predictive of human response, VESIcare should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

授乳期: It is not known whether solifenacin is excreted in human milk. Because many drugs are excreted in human milk, VESIcare **should not** be administered during nursing. A decision should be made whether to discontinue nursing or to discontinue VESIcare in nursing mothers.